Results 251 to 260 of about 81,753 (307)

The Novel HDAC Inhibitor OBP-801 Promotes MHC Class I Presentation Through LMP2 Upregulation, Enhancing the PD-1-Targeting Therapy in Clear Cell Renal Cell Carcinoma. [PDF]

Cancers (Basel)
Narukawa T, Yasuda S, Horinaka M, Taniguchi K, Tsujikawa T, Morita M, Ukimura O, Sakai T.   +7 more
europepmc   +1 more source

Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits estrogen receptor positive breast cancer cell growth. [PDF]

PLoS One
Jung M, Nicholas N, Grindrod S, Dritschilo A.   +3 more
europepmc   +1 more source

HDAC1 acts as tumor suppressor in ALK-positive anaplastic large-cell lymphoma: Implications for HDAC inhibitor therapy

Zrimšek M, Draganić K, Malzer A, Doblmayr V, de Freitas e Silva R, Wohlhaupter S, Perez Malla CU, Mišura K, Fischer H, Schachner H, Schiefer A, Sheibani-Tezerji R, Ellmeier W, Seiser C, Egger G.   +14 more
europepmc   +1 more source

HDAC inhibitor derivatives induce differentiation of leukemic cells through two distinct and separable mechanisms

Kumar P, Josa-Culleré L, Jackson TR, Bataille CJR, Vyas P, Milne TA, Russell AJ.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

NO-HDAC dual inhibitors

European Journal of Medicinal Chemistry, 2022
HDAC inhibitors and NO donors have both demonstrated independently broad therapeutic potential in a variety of diseases. Borretto et al. presented the topic of NO-HDAC dual inhibitors for the first time in 2013 as an attractive new topic. Here we collected the general structure of all synthesized NO-HDAC dual inhibitors, lead compounds, synthesis ...
Negar, Omidkhah, Razieh, Ghodsi
openaire   +2 more sources

HDAC Inhibitors

2016
Lysine acetylation in proteins is one of the most abundant posttranslational modifications in eukaryotic cells. The dynamic homeostasis of lysine acetylation and deacetylation is dictated by the action of histone acetyltransferases (HAT) and histone deacetylases (HDAC).
Heidi, Olzscha, Mina E, Bekheet, Semira, Sheikh, Nicholas B, La Thangue   +3 more
openaire   +2 more sources

Inside HDACs with more selective HDAC inhibitors

European Journal of Medicinal Chemistry, 2016
Inhibitors of histone deacetylases (HDACs) are nowadays part of the therapeutic arsenal mainly against cancers, with four compounds approved by the Food and Drug Administration. During the last five years, several groups have made continuous efforts to improve this class of compounds, designing more selective compounds or compounds with multiple ...
Roche, Joëlle, Bertrand, Philippe
openaire   +2 more sources